Allergan PLC (NYSE:AGN) CFO Maria Teresa Hilado purchased 1,422 shares of the firm’s stock in a transaction dated Friday, November 11th. The stock was bought at an average cost of $210.64 per share, for a total transaction of $299,530.08. Following the acquisition, the chief financial officer now directly owns 12,659 shares in the company, valued at $2,666,491.76. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Allergan PLC (NYSE:AGN) opened at 195.54 on Thursday. The firm’s 50-day moving average is $220.24 and its 200 day moving average is $234.18. Allergan PLC has a one year low of $186.34 and a one year high of $322.68. The stock has a market cap of $73.34 billion, a P/E ratio of 5.48 and a beta of 1.08.

Allergan PLC (NYSE:AGN) last posted its quarterly earnings data on Wednesday, November 2nd. The company reported $3.32 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.65 by $0.33. Allergan PLC had a net margin of 93.74% and a return on equity of 7.26%. The company had revenue of $3.62 billion for the quarter, compared to analyst estimates of $3.73 billion. During the same quarter last year, the company earned $3.48 EPS. The business’s revenue was up 4.4% compared to the same quarter last year. On average, analysts anticipate that Allergan PLC will post $13.37 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 28th. Stockholders of record on Tuesday, February 28th will be issued a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a dividend yield of 1.43%. This is an increase from Allergan PLC’s previous quarterly dividend of $0.05.

Several institutional investors have recently bought and sold shares of AGN. Barnett & Company Inc. bought a new position in Allergan PLC during the first quarter valued at about $111,000. Livingston Group Asset Management CO operating as Southport Capital Management bought a new position in Allergan PLC during the second quarter valued at about $125,000. Trust Co. of Vermont increased its position in Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock valued at $126,000 after buying an additional 89 shares during the period. Carroll Financial Associates Inc. increased its position in Allergan PLC by 68.7% in the third quarter. Carroll Financial Associates Inc. now owns 555 shares of the company’s stock valued at $127,000 after buying an additional 226 shares during the period. Finally, Integrated Investment Consultants LLC increased its position in Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock valued at $137,000 after buying an additional 154 shares during the period. Hedge funds and other institutional investors own 85.20% of the company’s stock.

Several equities analysts recently commented on AGN shares. Vetr lowered shares of Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $276.34 target price on the stock. in a report on Tuesday, August 2nd. JPMorgan Chase & Co. set a $325.00 target price on shares of Allergan PLC and gave the company a “buy” rating in a report on Friday, August 5th. Deutsche Bank AG reduced their target price on shares of Allergan PLC from $282.00 to $278.00 and set a “buy” rating on the stock in a report on Tuesday, August 9th. Leerink Swann set a $294.00 target price on shares of Allergan PLC and gave the company a “buy” rating in a report on Monday, August 8th. Finally, Mizuho raised shares of Allergan PLC from a “neutral” rating to a “buy” rating and increased their target price for the company from $248.00 to $318.00 in a report on Friday, August 19th. Six analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $290.07.

Allergan PLC Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

5 Day Chart for NYSE:AGN

Receive News & Stock Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related stocks with our FREE daily email newsletter.